HOME >> BIOLOGY >> NEWS
Suicidal Tendencies

NEW YORK, N.Y., June 20 -- Is the body made of minature samurais? In the July/August issue of The Sciences magazine Martin C. Raff, a biologist from University College, London, reports on his research, saying that virtually all cells are programmed to commit hari-kiri if their neighbors do not offer them continual support. If he's right, the findings could be good news for work on treating cancer, heart disease, Alzheimer's and Parkinson's disease.

With the exception of early fetal cells, all cells appear to have poisonous proteins stashed beneath their membranes. Like spies with cyanide pills under the skin, cells pack these suicidal enzymes away for extreme emergencies, releasing them only when neighboring cells drop out of communication. "Cellular neighborhoods seem to be more conformist than any middle-class suburb," Raff writes. "As long as the cells reproduce and behave according to local norms, they are allowed to go on living." One foot out of step, and the cell is history.

The interesting thing about Raff's research is that it suggests that suicide is the cell's default setting. The death machinery is always in place, ready to be activated. There are many evolutionary advantages to this set-up, Raff says in The Sciences. "Such a mechanism could ensure that any cell that ends up in the wrong place is automatically eliminated: isolated from its life-affirming partners, it quickly dispatches itself." A cell's suicidal tendencies may be an organism's key weapon in the fight against cancer and autoimmune diseases: cells that wander too far from their source of molecular signals naturally self-destruct. When the self-destruction mechanism is disrupted, though, cancerous tumors made up of rapidly reproducing cells can result.


'"/>

Contact: Ernie Knewitz
eknewitz@nyas.org
212-838-0230-231
New York Academy of Sciences
1-Jul-1996


Page: 1

Related biology news :

1. Suicidal behavior among alcoholics

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Suicidal Tendencies

(Date:5/20/2013)... 2013) - A novel vaccine study from ... research that will be unveiled at the American Association ... meeting takes place Monday, May 20 - Wednesday, May ... , "The main goal of a vaccine is ... pathogen that causes the disease", explained Dr. Hemachand Tummala, ...
(Date:5/19/2013)... at the University of California, Davis have engineered a ... for light. They report their findings today at ... Microbiology. , "In this work, we used synthetic biology ... carbon dioxide and light energy for growth) cyanobacterial metabolism ... Jordan McEwen, the lead researcher on the study. ...
(Date:5/17/2013)... (May 18, 2013) The AGA Research Foundation announced ... the relationship between the gut microbiota, one of today,s ... disease. , The AGA Research Awards Panel selected ... Massachusetts General Hospital and Harvard Medical School, Boston, as ... Dr. Chan will receive $25,000 of funding, commencing in ...
Breaking Biology News(10 mins):Germ-fighting vaccine system makes great strides in delivery 2New gut microbiome research to explore red meat -- colorectal cancer pathway 2
(Date:5/21/2013)... Alpha Source, Inc., a Wisconsin-based ... exhibiting for the 13th consecutive year at the ... 2013 Conference and Expo. The conference brings together ... healthcare technologies. This year’s event will be held ... , The three-day event draws over 1,500 healthcare ...
(Date:5/21/2013)... NC (PRWEB) May 21, 2013 ... financial services company for clinical trials, announced today ... Spend Solutions, LLC. Clinverse’s ClinPay® FLS eClinical ... investigator payment process. SpendMD ™, Aggregate ... complete solution for tracking and reporting transfer of ...
(Date:5/21/2013)... As the R&D sector becomes increasingly ... industry to deliver better products, faster. Collaborations between ... often means turning big ideas into reality, within ... with Sensidose AB and Recipharm, is one example ... market sooner. The partnership resulted in the development ...
(Date:5/21/2013)... ROCKVILLE, Md. , May 21, 2013 /PRNewswire/ ... "Phase 1 study of margetuximab (MGAH22), an Fc-modified ... solid tumors expressing the HER2 oncoprotein," will be ... American Society of Clinical Oncology during the Developmental ... June 3 at 4:15 – 4:30 PM.  The ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: